Substance Spotlight: Benzodiazepines — The Overlooked Crisis, and a First Glimpse of a Pharmacological Solution

The Quiet Emergency

Benzodiazepines — alprazolam (Xanax), diazepam (Valium), clonazepam (Klonopin), lorazepam (Ativan) and dozens of related compounds — are among the most widely prescribed and most dangerous drugs in America. Approximately 30 million Americans have a prescription. Roughly 2% of people entering substance use treatment programs report benzodiazepines as their primary drug, and mortality risk for people who use benzos is approximately double that of non-users after adjusting for other factors.

What makes benzodiazepine use disorder particularly difficult to treat is the withdrawal syndrome. Unlike opioid withdrawal — which is brutal but not acutely lethal in otherwise healthy adults — benzodiazepine withdrawal can cause seizures, psychosis, and death. The Ashton Manual, the standard reference for benzo withdrawal management, recommends tapers that can last 12 to 24 months. Cold-turkey discontinuation can kill. The medical complexity makes benzodiazepines the only common class of addictive drug where abrupt cessation is itself an emergency.

This is the context in which a new research finding matters enormously.

A Compound That Treats Addiction Without Triggering It

A study published in Translational Psychiatry has identified a compound called TPA023B as the most promising pharmacological candidate ever described for benzodiazepine use disorder — the first that could function as a genuine maintenance pharmacotherapy rather than a slow taper.

TPA023B is a GABA-A receptor modulator with a carefully engineered selectivity profile. Most benzodiazepines work by broadly enhancing the activity of GABA-A receptors across multiple subunit configurations. The α1 subunit drives sedation and the rewarding, abuse-driving effects of the drug class. The α2, α3, and α5 subunits drive anxiolytic effects without the same addiction liability.

TPA023B is a “silent allosteric modulator” at α1 — meaning it has no activity at the subunit that drives addiction — while functioning as a partial positive modulator at α2, α3, and α5. In practice: the compound reduces anxiety without delivering the rewarding signal that drives compulsive use.

What the Animal Data Shows

In rhesus monkeys trained to self-administer midazolam (a widely used benzodiazepine), TPA023B dose-dependently blocked drug-seeking behavior without suppressing food-seeking in the same animals. This distinction matters: most sedative medications suppress motivated behavior generally; TPA023B selectively targets the motivation to use the benzodiazepine while leaving other motivation intact.

More remarkable: TPA023B did not precipitate acute withdrawal syndrome when administered, and it reversed withdrawal-like effects induced by flumazenil (a drug that blocks benzodiazepine receptors and typically precipitates severe withdrawal in dependent animals). This suggests TPA023B could potentially be used not just for long-term maintenance but for acute management of withdrawal itself.

The dosing range that achieved these effects corresponds to approximately 70–80% receptor site occupancy — levels documented in prior human PET scanning studies to be achievable at tolerated doses. The translational pathway from primate to human, while never guaranteed, has clearer milestones than most preclinical candidates.

Where the Field Disagrees

The main tension in the benzo treatment field is between slow-taper advocates (the Ashton approach, emphasizing long diazepam substitution tapers) and those who see the lack of a pharmacological maintenance option as the defining gap. Slow tapers work — with a roughly 65% long-term abstinence rate when combined with CBT — but they require months to years of clinical attention and do not address the anxiety disorders that frequently underlie benzo dependence in the first place.

Some researchers also caution that a partial agonist like TPA023B, by maintaining some GABA-A activity, could itself become a maintenance drug with its own dependency profile. The preclinical data address this partly — the compound did not support self-administration in animals — but long-term human data will be essential before any conclusions about clinical dependency risk can be drawn.

What’s in the Pipeline

Beyond TPA023B, baclofen — a GABA-B agonist used for muscle spasticity — is in active clinical trials for benzo dependence, based on evidence that GABA-B modulation can ease the severity of GABA-A withdrawal symptoms. And the GLP-1 receptor agonist signal emerging from alcohol and stimulant data (see today’s research roundup) may eventually extend to benzo use disorder, given shared reward-circuit involvement.

And the GLP-1 receptor agonist signal emerging from alcohol and stimulant data (see today’s research roundup) may eventually extend to benzo use disorder, given shared reward-circuit involvement.

Resources and Crisis Support

If you or someone you love is physically dependent on benzodiazepines, do not stop abruptly. Withdrawal management must be medically supervised.

Rize Recovery’s facility matching tool can help find programs with medically supervised detox specifically for CNS depressant dependence. Find a detox program.

988 Suicide and Crisis Lifeline: call or text 988 — available 24/7 for substance-related mental health crises.

SAMHSA National Helpline: 1-800-662-4357 — free, confidential, 24/7 treatment referral.